FDA approves Abbvies new JAK1 inhibitor - upadacitinib (named Rinvok) Package insert - indicated for use in mod. to severely active RA not resp to MTX (do not combine w/ other JAKS, biologics). 15 mg qd. Warning for VTE, DVT. https://t.co/9KODynuWKC https://t.co/zRpeiaiTNS